Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer

BACKGROUND: Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival. We studied the dynamics of biomarker changes with imaging and b...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Vaishampayan, Ulka N., Podgorski, Izabela, Heilbrun, Lance K., Lawhorn-Crews, Jawana M., Dobson, Kimberlee C., Boerner, Julie, Stark, Karri, Smith, Daryn W., Heath, Elisabeth I., Fontana, Joseph A., Shields, Anthony F.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335157/
https://ncbi.nlm.nih.gov/pubmed/30327304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1473
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы